Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matisyahu Shulman

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Journal of Addiction Medicine|February 11, 2020
Secondary Analysis of Pain Outcomes in a Large Pragmatic Randomized Trial of Buprenorphine/Naloxone Versus Methadone for Opioid Use DisorderMatisyahu Shulman, Sean X Luo, Aimee N C Campbell, et al.
Journal of Substance Use and Addiction Treatment|December 9, 2025
A clinical trial loses access to some of its experimental treatment conditions: What can be done?Sarah Meyers-Ohki, Matisyahu Shulman, Roger D Weiss, et al.
Drug and Alcohol Dependence|September 8, 2022
Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorderKara E Rudolph, Nicholas T Williams, Alicia T Singham Goodwin, et al.
Addiction (Abingdon, England)|December 19, 2020
Explaining differential effects of medication for opioid use disorder using a novel approach incorporating mediating variablesKara E Rudolph, Iván Díaz, Nima S Hejazi, et al.
Journal of Addiction Medicine|October 3, 2023
Secondary Analysis of Agreement Between Negative Timeline Follow Back Report and Negative Urine Toxicology in a Large Trial of Individuals with Opioid Use DisorderMatisyahu Shulman, Tse-Hwei Choo, Jennifer Scodes, et al.
Drug and Alcohol Dependence|May 23, 2022
Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexoneJudith I Tsui, Aimee N C Campbell, Martina Pavlicova, et al.
Substance Use & Misuse|April 3, 2026
Patient Characteristics Associated with Successful Initiation of Extended-Release Naltrexone in the X:BOT TrialKenzie Potter, Miranda Greiner, Matisyahu Shulman, et al.
European Journal of Dental Education : Official Journal of the Association for Dental Education in Europe|January 20, 2021
The utility of a formative one-station objective structured clinical examination for Substance use disorders in a dental curriculumFolarin Odusola, Jennifer L Smith, Eva Turrigiano, et al.
Journal of Substance Abuse Treatment|March 27, 2021
Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failureMatisyahu Shulman, Tse-Hwei Choo, Jennifer Scodes, et al.
Journal of Substance Abuse Treatment|June 7, 2021
Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapseMiranda G Greiner, Matisyahu Shulman, Tse-Hwei Choo, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Journal of Addiction Medicine|February 11, 2020
Secondary Analysis of Pain Outcomes in a Large Pragmatic Randomized Trial of Buprenorphine/Naloxone Versus Methadone for Opioid Use DisorderMatisyahu Shulman, Sean X Luo, Aimee N C Campbell, et al.
Journal of Substance Use and Addiction Treatment|December 9, 2025
A clinical trial loses access to some of its experimental treatment conditions: What can be done?Sarah Meyers-Ohki, Matisyahu Shulman, Roger D Weiss, et al.
Drug and Alcohol Dependence|September 8, 2022
Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorderKara E Rudolph, Nicholas T Williams, Alicia T Singham Goodwin, et al.
Addiction (Abingdon, England)|December 19, 2020
Explaining differential effects of medication for opioid use disorder using a novel approach incorporating mediating variablesKara E Rudolph, Iván Díaz, Nima S Hejazi, et al.
Journal of Addiction Medicine|October 3, 2023
Secondary Analysis of Agreement Between Negative Timeline Follow Back Report and Negative Urine Toxicology in a Large Trial of Individuals with Opioid Use DisorderMatisyahu Shulman, Tse-Hwei Choo, Jennifer Scodes, et al.
Drug and Alcohol Dependence|May 23, 2022
Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexoneJudith I Tsui, Aimee N C Campbell, Martina Pavlicova, et al.
Substance Use & Misuse|April 3, 2026
Patient Characteristics Associated with Successful Initiation of Extended-Release Naltrexone in the X:BOT TrialKenzie Potter, Miranda Greiner, Matisyahu Shulman, et al.
European Journal of Dental Education : Official Journal of the Association for Dental Education in Europe|January 20, 2021
The utility of a formative one-station objective structured clinical examination for Substance use disorders in a dental curriculumFolarin Odusola, Jennifer L Smith, Eva Turrigiano, et al.
Journal of Substance Abuse Treatment|March 27, 2021
Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failureMatisyahu Shulman, Tse-Hwei Choo, Jennifer Scodes, et al.
Journal of Substance Abuse Treatment|June 7, 2021
Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapseMiranda G Greiner, Matisyahu Shulman, Tse-Hwei Choo, et al.
Pageof 4